Figure 3.

AG3340 inhibits transendothelial migration of IS-CD8⁺ T cells and delays the onset of transferred diabetes in NOD mice. (A) AG3340 inhibits the transmigration of IS-CD8⁺ cells into the pancreatic islets. Mice received AG3340, SB-3CT, EGCG or PBS 30 min prior to the injection of the cells. IS-CD8⁺ cells were labeled with DiI and then injected in NOD mice. In 24 h, the labeled cells with their intra-islet location were counted in the cryostat sections of the entire pancreas. (B) AG3340 delays the onset of adoptively transferred diabetes in NOD mice. IS-CD8⁺ cells were injected in NOD mice. Mice received AG3340, SB-3CT,EGCG or PBS by one injection every other day until they developed diabetes (approximately 1–2 weeks). The onset of diabetes was monitored daily by measuring urine glucose levels with Diastix reagent strips. Mice with urine glucose levels of ≥300 mg/dl for 3 consecutive days were considered diabetic. ^*P=0.02, ^**P=0.015 by Fisher’s test. AG3340, 3(S)-2,2-dimethyl-4[4-pyridin-4-yloxy-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxamate; NOD, non-obese diabetic; SB-3CT, 2-(4-phenoxyphenylsulfonylmethyl)thiirane; EGCG, epigallocatechin-3-gallate; DiI, didodecyl-tetramethylindocarbocyanine perchlorate.